462 related articles for article (PubMed ID: 16093440)
1. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
2. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.
Lee SO; Nadiminty N; Wu XX; Lou W; Dong Y; Ip C; Onate SA; Gao AC
Cancer Res; 2005 Apr; 65(8):3487-92. PubMed ID: 15833885
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
4. Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells.
Li Z; Carrier L; Rowan BG
Mol Cancer Ther; 2008 Sep; 7(9):3056-63. PubMed ID: 18790785
[TBL] [Abstract][Full Text] [Related]
5. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.
Coopman P; Garcia M; Brünner N; Derocq D; Clarke R; Rochefort H
Int J Cancer; 1994 Jan; 56(2):295-300. PubMed ID: 8314314
[TBL] [Abstract][Full Text] [Related]
6. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of estrogen receptor alpha (ERalpha) signaling by selenium in breast cancer cells via downregulation of ERalpha gene expression.
Shah YM; Kaul A; Dong Y; Ip C; Rowan BG
Breast Cancer Res Treat; 2005 Aug; 92(3):239-50. PubMed ID: 16155795
[TBL] [Abstract][Full Text] [Related]
8. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
Castro-Rivera E; Safe S
J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
[TBL] [Abstract][Full Text] [Related]
9. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.
Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M
Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620
[TBL] [Abstract][Full Text] [Related]
10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
11. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Metabolism as a Therapeutic Option for Tamoxifen-Resistant Breast Cancer Cells.
Steifensand F; Gallwas J; Bauerschmitz G; Gründker C
Cells; 2021 Sep; 10(9):. PubMed ID: 34572047
[TBL] [Abstract][Full Text] [Related]
15. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
16. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells.
Sakamoto T; Eguchi H; Omoto Y; Ayabe T; Mori H; Hayashi S
Mol Cell Endocrinol; 2002 Jun; 192(1-2):93-104. PubMed ID: 12088871
[TBL] [Abstract][Full Text] [Related]
18. Distinct effects of gonadotropin-releasing hormone analogs and 4-hydroxytamoxifen on pS2 mRNA expression with respect to cell proliferation in MCF-7 breast cancer cells.
Neri C; Colomb E; Roux-Dosseto M; Martin PM
Anticancer Res; 1991; 11(1):411-5. PubMed ID: 1826824
[TBL] [Abstract][Full Text] [Related]
19. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
